600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ERBB2-Negative Advanced Breast Cancer

Overview of attention for article published in JAMA Oncology, November 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 2 news outlets
twitter: 90 X users

guideline: 1 clinical guideline source
bluesky: 3 Bluesky users

Readers on

mendeley: 13 Mendeley

So far, Altmetric has seen 5 news stories from 2 outlets.

Rethinking Ribociclib: 400 mg vs 600 mg in Metastatic BC

Medscape, 11 Nov 2025

This transcript has been edited for clarity. Hi. It's Dr Kathy Miller, from Indiana University, back with you today to think…

Schützen Tattoos vor Hautkrebs?; Krebsrisiken durch die Bildgebung; Mortalität beim Prostata-Ca durch den Lebensstil senken

Medscape, 30 Sep 2025

Im Onko-Blog dieser Woche berichten wir über diese neuen Studien und Themen, welche die Krebstherapie verbessern können…

Sergio Cifuentes: Could a Lower Dose of Ribociclib be Safer Yet Still Effective in HR+/HER2 Breast Cancer? - OncoDaily

Oncodaily, 28 Sep 2025

Sergio Cifuentes, Medical Oncologist at Las Américas Auna Clinic, shared a post on X: “AMALEE Trial – Ribociclib 400 mg vs 600…

600 mg vs 400 mg Ribociclib in HR+/ERBB2: Advanced Breast Cancer - JAMA Oncology - OncoDaily

Oncodaily, 27 Sep 2025

Fatima Cardoso/myoncologia.pt JAMA Oncology shared a post on LinkedIn: “A 400-mg ribociclib starting dose did not match the…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 1 additional news stories.